A DNA binding mutation in estrogen receptor-α Leads to suppression of Wnt signaling via β-catenin destabilization in osteoblasts

Journal of Cellular Biochemistry

Volumn 113, Issue 7, 2012, Pages 2248-2255

  Mödder, Ulrike I ^a   Rudnik, Volha ^a   Liu, Gang ^a   Khosla, Sundeep ^a   Monroe, David G ^a  

^a MAYO CLINIC   (United States)

Author keywords

catenin; bone; Estrogen receptor; nerki; Wnt

Indexed keywords

BETA CATENIN; BETA GALACTOSIDASE; DNA; ESTROGEN RECEPTOR ALPHA; LYMPHOID ENHANCER FACTOR 1; WNT PROTEIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DNA BINDING; ENZYME ACTIVITY; FEMALE; GENE EXPRESSION; GENE MUTATION; IN VIVO STUDY; MOUSE; NONHUMAN; OSTEOBLAST; PHENOTYPE; PRIORITY JOURNAL; PROTEIN FUNCTION; SIGNAL TRANSDUCTION;

ANIMALS; BETA CATENIN; DNA; DNA-BINDING PROTEINS; ESTROGEN RECEPTOR ALPHA; FEMALE; LYMPHOID ENHANCER-BINDING FACTOR 1; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MUTATION; OSTEOBLASTS; TRANSCRIPTION, GENETIC; WNT PROTEINS; WNT SIGNALING PATHWAY;

MUS; MUS MUSCULUS;

EID: 84861021168     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.24095     Document Type: Article

References (37)

1. Armstrong VJ, Muzylak M, Sunters A, Zaman G, Saxon LK, Price JS, Lanyon LE,. 2007. Wnt/beta-catenin signaling is a component of osteoblastic bone cell early responses to load-bearing and requires estrogen receptor alpha. J Biol Chem 282: 20715-20727.
2. Balemans W, Patel N, Ebeling M, Van Hul E, Wuyts W, Lacza C, Dioszegi M, Dikkers FG, Hildering P, Willems PJ, Verheij JB, Lindpaintner K, Vickery B, Foernzler D, Van Hul W,. 2002. Identification of a 52 kb deletion downstream of the SOST gene in patients with van Buchem disease. J Med Genet 39: 91-97.
3. Baron R, Rawadi G,. 2007. Wnt signaling and the regulation of bone mass. Curr Osteoporos Rep 5: 73-80.
4. Bonnelye E, Aubin JE,. 2005. Review: Estrogen receptor-related receptor alpha: A mediator of estrogen response in bone. J Clin Endocrinol Metab 90: 3115-3121.
5. Cho HY, Choi HJ, Sun HJ, Yang JY, An JH, Cho SW, Kim SW, Kim SY, Kim JE, Shin CS,. 2010. Transgenic mice overexpressing secreted frizzled-related proteins (sFRP)4 under the control of serum amyloid P promoter exhibit low bone mass but did not result in disturbed phosphate homeostasis. Bone 47: 263-271.
6. DasGupta R, Fuchs E,. 1999. Multiple roles for activated LEF/TCF transcription complexes during hair follicle development and differentiation. Development 126: 4557-4568.
7. Fleming HE, Janzen V, Lo Celso C, Guo J, Leahy KM, Kronenberg HM, Scadden DT,. 2008. Wnt signaling in the niche enforces hematopoietic stem cell quiescence and is necessary to preserve self-renewal in vivo. Cell Stem Cell 2: 274-283.
8. Guo J, Liu M, Yang D, Bouxsein ML, Saito H, Galvin RJ, Kuhstoss SA, Thomas CC, Schipani E, Baron R, Bringhurst FR, Kronenberg HM,. 2010. Suppression of Wnt signaling by Dkk1 attenuates PTH-mediated stromal cell response and new bone formation. Cell Metabol 11: 161-171.
9. Imai Y, Youn MY, Kondoh S, Nakamura T, Kouzmenko A, Matsumoto T, Takada I, Takaoka K, Kato S,. 2009. Estrogens maintain bone mass by regulating expression of genes controlling function and life span in mature osteoclasts. Ann N Y Acad Sci 1173 (Suppl 1): E31-E39.
10. Jakacka M, Ito M, Weiss J, Chien P-Y, Gehm BD, Jameson JL,. 2001. Estrogen receptor binding to DNA is not required for its activity through the nonclassical AP1 pathway. J Biol Chem 276: 13615-13621.
11. Jakacka M, Ito M, Martinson F, Ishikawa T, Lee EJ, Jameson JL,. 2002. An estrogen receptor (ER)alpha deoxyribonucleic acid-binding domain knock-in mutation provides evidence for nonclassical ER pathway signaling in vivo. Mol Endocrinol 16: 2188-2201.
12. Kouzmenko AP, Takeyama K, Ito S, Furutani T, Sawatsubashi S, Maki A, Suzuki E, Kawasaki Y, Akiyama T, Tabata T, Kato S,. 2004. Wnt/beta-catenin and estrogen signaling converge in vivo. J Biol Chem 279: 40255-40258.
13. Krause C, Korchynskyi O, de Rooij K, Weidauer SE, de Gorter DJ, van Bezooijen RL, Hatsell S, Economides AN, Mueller TD, Lowik CW, ten Dijke P,. 2010. Distinct modes of inhibition by sclerostin on bone morphogenetic protein and Wnt signaling pathways. J Biol Chem 285: 41614-41626.
14. Li J, Sarosi I, Cattley RC, Pretorius J, Asuncion F, Grisanti M, Morony S, Adamu S, Geng Z, Qiu W, Kostenuik P, Lacey DL, Simonet WS, Bolon B, Qian X, Shalhoub V, Ominsky MS, Zhu Ke H, Li X, Richards WG,. 2006. Dkk1-mediated inhibition of Wnt signaling in bone results in osteopenia. Bone 39: 754-766.
15. Loots GG, Kneissel M, Keller H, Baptist M, Chang J, Collette NM, Ovcharenko D, Plajzer-Frick I, Rubin EM,. 2005. Genomic deletion of a long-range bone enhancer misregulates sclerostin in Van Buchem disease. Genome Res 15: 928-935.
16. MacDonald BT, Adamska M, Meisler MH,. 2004. Hypomorphic expression of Dkk1 in the doubleridge mouse: Dose dependence and compensatory interactions with Lrp6. Development 131: 2543-2552.
17. MacDonald BT, Joiner DM, Oyserman SM, Sharma P, Goldstein SA, He X, Hauschka PV,. 2007. Bone mass is inversely proportional to Dkk1 levels in mice. Bone 41: 331-339.
18. Modder UI, Oursler MJ, Khosla S, Monroe DG,. 2011a. Wnt10b activates the Wnt, notch, and NFkappaB pathways in U2OS osteosarcoma cells. J Cell Biochem 112: 1392-1402.
19. Modder UI, Roforth MM, Hoey K, McCready LK, Peterson JM, Monroe DG, Oursler MJ, Khosla S,. 2011b. Effects of estrogen on osteoprogenitor cells and cytokines/bone-regulatory factors in postmenopausal women. Bone 49: 202-207.
20. Moeller MJ, Soofi A, Sanden S, Floege J, Kriz W, Holzman LB,. 2005. An efficient system for tissue-specific overexpression of transgenes in podocytes in vivo. Am J Physiol Renal Physiol 289: F481-F488.
21. Monroe DG, Getz BJ, Johnsen SA, Riggs BL, Khosla S, Spelsberg TC,. 2003. Estrogen receptor isoform-specific regulation of endogenous gene expression in human osteoblastic cell lines expressing either ERalpha or ERbeta. J Cell Biochem 90: 315-326.
22. Monroe DG, Spelsberg TC, Khosla S,. 2006. Sex steroid effects on bone metabolism. In:, Seibel MJ, Robins SP, Bilezikian JP, editors. Dynamics of bone and cargilage metabolism. San Diego, CA: Academic Press. pp 327-343.
23. Monroe DG, McGee-Lawrence ME, Oursler MJ, Westendorf JJ,. 2012. Update on Wnt signaling in bone cell biology and bone disease. Gene 492: 1-18.
24. Morvan F, Boulukos K, Clement-Lacroix P, Roman Roman S, Suc-Royer I, Vayssiere B, Ammann P, Martin P, Pinho S, Pognonec P, Mollat P, Niehrs C, Baron R, Rawadi G,. 2006. Deletion of a single allele of the Dkk1 gene leads to an increase in bone formation and bone mass. J Bone Miner Res 21: 934-945.
25. Nakanishi R, Akiyama H, Kimura H, Otsuki B, Shimizu M, Tsuboyama T, Nakamura T,. 2008. Osteoblast-targeted expression of Sfrp4 in mice results in low bone mass. J Bone Miner Res 23: 271-277.
26. Noh T, Gabet Y, Cogan J, Shi Y, Tank A, Sasaki T, Criswell B, Dixon A, Lee C, Tam J, Kohler T, Segev E, Kockeritz L, Woodgett J, Muller R, Chai Y, Smith E, Bab I, Frenkel B,. 2009. Lef1 haploinsufficient mice display a low turnover and low bone mass phenotype in a gender- and age-specific manner. PLoS ONE 4: e5438.
27. O'Brien PC,. 1984. Procedures for comparing samples with multiple endpoints. Biometrics 40: 1079-1087.
28. Salie R, Li H, Jiang X, Rowe DW, Kalajzic I, Susa M,. 2008. A rapid, nonradioactive in situ hybridization technique for use on cryosectioned adult mouse bone. Calcif Tissue Int 83: 212-221.
29. Sims NA, Dupont S, Krust A, Clement-LaCroix P, Minet D, Resche-Rigon M, Gaillard-Kelly M, Baron R,. 2002. Deletion of estrogen receptors reveals a regulatory role for estrogen receptors beta in bone remodeling in females but not in males. Bone 30: 18-25.
30. Syed FA, Modder UI, Fraser DG, Spelsberg TC, Rosen CJ, Krust A, Chambon P, Jameson JL, Khosla S,. 2005. Skeletal effects of estrogen are mediated by opposing actions of classical and nonclassical estrogen receptor pathways. J Bone Miner Res 20: 1992-2001.
31. Syed FA, Fraser DG, Spelsberg TC, Rosen CJ, Krust A, Chambon P, Jameson JL, Khosla S,. 2007. Effects of loss of classical estrogen response element signaling on bone in male mice. Endocrinology 148: 1902-1910.
32. van Genderen C, Okamura RM, Farinas I, Quo RG, Parslow TG, Bruhn L, Grosschedl R,. 1994. Development of several organs that require inductive epithelial-mesenchymal interactions is impaired in LEF-1-deficient mice. Genes Dev 8: 2691-2703.
33. Windahl SH, Vidal O, Andersson G, Gustafsson JA, Ohlsson C,. 1999. Increased cortical bone mineral content but unchanged trabecular bone mineral density in female ER beta -/- mice. J Clin Invest 104: 895-901.
34. Windahl SH, Hollberg K, Vidal O, Gustafsson J-A, Ohlsson C, Andersson G,. 2001. Female estrogen receptor B-/- mice are partially protected against age-related trabecular bone loss. J Bone Miner Res 16: 1388-1398.
35. Winkler DG, Sutherland MK, Geoghegan JC, Yu C, Hayes T, Skonier JE, Shpektor D, Jonas M, Kovacevich BR, Staehling-Hampton K, Appleby M, Brunkow ME, Latham JA,. 2003. Osteocyte control of bone formation via sclerostin, a novel BMP antagonist. EMBO J 22: 6267-6276.
36. Yao GQ, Wu JJ, Troiano N, Insogna K,. 2011. Targeted overexpression of Dkk1 in osteoblasts reduces bone mass but does not impair the anabolic response to intermittent PTH treatment in mice. J Bone Miner Metab 29: 141-148.
37. Yu HM, Jerchow B, Sheu TJ, Liu B, Costantini F, Puzas JE, Birchmeier W, Hsu W,. 2005. The role of Axin2 in calvarial morphogenesis and craniosynostosis. Development 132: 1995-2005.